GLP-2 research peptides are studied for intestinal growth and mucosal repair. Learn how GLP-2 works, how it differs from GLP-1, and safety considerations.
GLP-2 research peptides are laboratory-grade forms of glucagon-like peptide-2, a 33-amino-acid gut hormone that supports intestinal growth, mucosal repair, and nutrient absorption. Scientists use them to study how the intestine adapts after injury, surgery, or disease, and to map GLP-2 receptor signaling at the cellular level. They are reference compounds sold for research only, and GLP-2 peptides are not FDA-approved for human use.
What Are GLP-2 Research Peptides?
GLP-2 is produced and secreted by enteroendocrine L-cells in the ileum and colon, usually alongside GLP-1, after nutrient intake. The native human peptide is 33 amino acids long and is cleaved quickly by the enzyme DPP-4, which gives it a circulating half-life measured in minutes.
In a research catalog, the term GLP-2 research peptides usually refers to one of three categories:
- Native human GLP-2 (1-33) — the reference standard used in binding and signaling assays.
- DPP-4-resistant analogs such as teduglutide, in which a single amino acid substitution at position 2 extends half-life.
- Long-acting analogs like glepaglutide and apraglutide, which carry fatty acid or other modifications for extended exposure in preclinical models.
Vials are typically supplied as lyophilized powder with purity between 95% and 98%, plus a certificate of analysis listing HPLC and mass spectrometry results. Sequence, salt form, and endotoxin status all matter when results are compared across suppliers.
How GLP-2 Signaling Works in the Intestine
The GLP-2 receptor is a class B G-protein-coupled receptor expressed on enteric neurons, subepithelial myofibroblasts, and enteroendocrine cells. Activation triggers downstream pathways, including IGF-1 and ErbB ligand signaling, that act on the intestinal crypt and villus.
Documented effects in preclinical and clinical research
- Increased crypt cell proliferation and reduced epithelial apoptosis.
- Taller villi and greater mucosal surface area in animal models.
- Reduced intestinal permeability and tighter epithelial barrier function.
- Slowed gastric emptying and reduced gastric acid secretion.
- Improved fluid and nutrient absorption in short bowel models.
Labs that study GLP-2 often also research glp-1 peptides, because the two hormones are co-secreted and share overlapping metabolic readouts. Keeping the assays separate matters, since GLP-2 does not drive insulin secretion the way GLP-1 does.
GLP-2 vs. GLP-1: Key Research Differences
| Feature | GLP-1 | GLP-2 |
|---|---|---|
| Typical length | 30-31 amino acids | 33 amino acids |
| Primary source | L-cells (ileum, colon) | L-cells (ileum, colon) |
| Receptor | GLP-1R | GLP-2R |
| Main research focus | Glucose-dependent insulin release, appetite, gastric emptying | Intestinal growth, mucosal healing, absorption |
| DPP-4 stability | Rapidly degraded | Rapidly degraded |
| Approved drug examples | Semaglutide, liraglutide, dulaglutide | Teduglutide |
Because the receptor targets are different, GLP-1 and GLP-2 peptides are not interchangeable in assays. A GLP-1R reporter line will not respond to GLP-2, and GLP-2R activation does not produce the incretin effect that defines GLP-1 activity.
Commonly Studied GLP-2 Analogs
| Compound | Key modification | Reported half-life | Development status |
|---|---|---|---|
| Native GLP-2 (1-33) | None | Minutes | Reference standard |
| Teduglutide | Gly substitution at position 2 (DPP-4 resistance) | Approximately 2-3 hours after subcutaneous dosing | FDA-approved for short bowel syndrome |
| Glepaglutide | Fatty acid chain extension | Extended (multi-hour to multi-day) | Investigational |
| Apraglutide | Non-proteinogenic amino acid substitution | Extended (multi-hour to multi-day) | Investigational |
What the Evidence Shows, and Where It Is Still Early
The strongest human evidence for GLP-2 signaling comes from short bowel syndrome. In trials of teduglutide, some patients reduced their dependence on parenteral nutrition, and the drug remains prescription-only with required medical monitoring.
Research interest also extends to chemotherapy- and radiation-induced mucositis, intestinal adaptation after resection, and inflammatory bowel disease. Results in IBD models have been mixed, and no GLP-2 peptide is approved for that indication. Animal models and healthy volunteers do not always predict outcomes in patients with severe intestinal failure.
Anyone searching for glp-1 research peptides where to buy online will notice that GLP-2 products share the same catalogs, but the two categories answer separate research questions.
Sourcing, Handling, and Quality Control
Sourcing decisions affect data quality more than most people expect. A vendor advertising top research peptides should supply a lot-specific certificate of analysis with HPLC purity, mass spectrometry identity confirmation, and endotoxin data.
When comparing suppliers such as aavant research peptides, confirm the sequence matches your protocol, ask whether the peptide is the TFA or acetate salt, and check that shipping uses cold packs. Regulators have also flagged products marketed as disguised research peptides when the real intent is human use.
Handling basics for lyophilized GLP-2:
- Store powder at -20 °C or lower, with vials sealed and desiccated.
- Reconstitute with sterile water or a compatible buffer, and avoid vortexing, which can shear the peptide.
- Aliquot before freezing to prevent repeated freeze-thaw cycles.
- Use low-protein-binding tubes for dilute working stocks.
- Discard solutions that turn cloudy or show precipitation.
Run a vehicle control and, where possible, a known GLP-2R agonist or antagonist alongside test articles so the assay window is documented in the same plate or run.
Safety, Legal Status, and Responsible Use
GLP-2 research peptides are sold for laboratory use only and are not FDA-approved for human use in the United States.
Peptides labeled research-use-only are not reviewed by the FDA for safety, purity, or effectiveness. Teduglutide is the only GLP-2-based medicine approved in the United States, and it is dispensed by prescription with ongoing clinical monitoring.
In clinical studies, GLP-2 analogs have been associated with fluid retention, injection site reactions, and gastrointestinal effects. Product labels and trial reports also describe risks such as intestinal obstruction and acceleration of intestinal neoplasia in predisposed patients. Anyone considering a GLP-2-based therapy should speak with a licensed healthcare professional instead of self-experimenting with research-grade material.
Frequently Asked Questions
What are GLP-2 research peptides used for?
GLP-2 research peptides are used in laboratory studies of intestinal growth, mucosal healing, barrier function, and nutrient absorption. Researchers also use them to characterize GLP-2 receptor signaling and to compare native GLP-2 with longer-acting analogs such as teduglutide. They are not approved for human use outside of prescription medicines.
Is GLP-2 the same as GLP-1?
No. GLP-1 and GLP-2 are separate hormones that are co-secreted by intestinal L-cells but bind different receptors. GLP-1 research focuses on insulin secretion, appetite, and gastric emptying, while GLP-2 research focuses on intestinal growth and mucosal repair. The two peptides are not interchangeable in assays.
Are GLP-2 research peptides legal and FDA-approved?
Research peptides can generally be purchased for laboratory use, but they are not FDA-approved for human consumption and are not reviewed for safety, purity, or effectiveness. Only teduglutide, a prescription GLP-2 analog, is approved in the United States for a specific medical condition. Buyers should verify supplier documentation and comply with applicable federal and state rules.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.